Synaptic Pharmaceutical Corporation

Neurogenetic Corporation

H. Lundbeck A/s

The Dupont Merck Pharmaceutical Company

Paul R Hartig

Theresa A Branchek

Richard L Weinshank

Charles Gluchowski

George Chiu

John M Wetzel

Carlos C Forray

Kelli E Smith

Laurence A Borden

Christophe P Gerald

Hung-Teh Kao

Wendell W Wilkerson

Richard A Earl

Christopher A Teleha

Robert Zaczek

Barry Stephen Brown

Simon Piers Aiken

This invention provides isolated nucleic acid molecules encoding a human dopamine Dreceptor, isolated proteins which are human dopamine Dreceptor, vectors comprising isolated nucleic acid molecules encoding a human dopamine Dreceptor, mammalian cells comprising such vectors, antibodies directed to a human dopamine Dreceptor, nucleic acid probes useful for detecting nucleic acid encoding human dopamine Dreceptor, antisense oligonucleotides complementary to any sequences of a nucleic acid molecule which encodes a human dopamine Dreceptor, pharmaceutical compounds related to human dopamine Dreceptor, and nonhuman transgenic animals which express DNA a normal or a mutant human dopamine Dreceptor. This invention further provides methods for determining ligand binding, detecting expression, drug screening, and treatment involving a human dopamine Dreceptor.

DNA encoding a human dopamine D1 receptor and uses thereof

A method of treating benign prostatic hyperplasia in a subject which comprises administering to the subject a therapeutically effective amount of a compound which binds to a human &agr; adrenergic receptor with a binding affinity greater than ten-fold higher than the binding affinity with which the compound binds to a human &agr; adrenergic receptor, a human &agr; adrenergic receptor, and a human histamine H receptor, and, binds to a human &agr; adrenergic receptor with a binding affinity which is greater than ten-fold lower than the binding affinity with which the compound binds to such &agr; adrenergic receptor. Compounds meeting these criteria are provided.

Use of &agr;1C specific compounds to treat benign prostatic hyperplasia

This invention provides isolated nucleic acid molecules encoding human 5-HT receptors, isolated proteins which are human 5-HT receptors, vectors comprising isolated nucleic acid molecules encoding human 5-HT receptors, mammalian cells comprising such vectors, antibodies directed to human 5-HT receptors, nucleic acid probes useful for detecting nucleic acid encoding human 5-HT receptors, antisense oligonucleotides complementary to any sequences of a nucleic acid molecule which encodes a human 5-HT receptor, pharmaceutical compounds related to human 5-HT receptors, and nonhuman transgenic animals which express DNA which encodes a normal or a mutant human 5-HT receptor. This invention further provides methods for determining ligand binding, detecting expression, drug screening, and treatment involving the human 5-HT receptor.

Method of obtaining a composition comprising a 5-HT1D selective compound

This invention provides isolated nucleic acid molecules encoding a human dopamine D receptor, isolated proteins which are human dopamine D receptor, vectors comprising isolated nucleic acid molecules encoding a human dopamine D receptor, mammalian cells comprising such vectors, antibodies directed to a human dopamine D receptor, nucleic acid probes useful for detecting nucleic acid encoding human dopamine D receptor, antisense oligonucleotides complementary to any sequences of a nucleic acid molecule which encodes a human dopamine D receptor, pharmaceutical compounds related to human dopamine D receptor, and nonhuman transgenic animals which express DNA a normal or a mutant human dopamine D receptor. This invention further provides methods for determining ligand binding, detecting expression, drug screening, and treatment involving a human dopamine D receptor.

This invention provides an isolated nucleic acid molecule encoding a human 5-HT receptor, an isolated protein which is a human 5-HT receptor, vectors comprising an isolated nucleic acid molecule encoding a human 5-HT receptors, mammalian cells comprising such vectors, antibodies directed to the human 5-HT receptor, nucleic acid probes useful for detecting nucleic acid encoding human 5-HT receptors, antisense oligonucleotides complementary to any sequences of a nucleic acid molecule which encodes a human 5-HT receptor, pharmaceutical compounds related to human 5-HT receptors, and nonhuman transgenic animals which express DNA a normal or a mutant human 5-HT receptor. This invention further provides methods for determining ligand binding, detecting expression, drug screening, and treatment involving the human 5-HT receptor.

DNA encoding a 5-HT 1F receptor and uses thereof

The present invention provides a method of obtaining a composition which comprises determining whether a chemical compound binds to a human 5-HT receptor expressed on the surface of a mammalian cell transfected with a vector adapted for expressing the receptor in the cell, and if the compound binds to the receptor, admixing the compound with a carrier. The present invention further provides a method of obtaining a composition which comprises determining whether a chemical compound binds to and activates or binds to and inhibits activation of a human 5-HT receptor expressed on the surface of a mammalian cell, wherein the human 5-HT receptor is expressed on the surface of a mammalian cell transfected with a vector adapted for expressing the receptor in the cell, and if the compound binds to and activates or binds to and inhibits activation of the receptor, admixing the compound with a carrier.

Methods of obtaining compounds that interact with a human serotonin (5-HT2) receptor

The present invention provides a process for identifying a chemical compound which specifically binds to a rat or human 5-HT,receptor. The invention also provides a process involving competitive binding for identifying a chemical compound which specifically binds to a rat or human 5-HT,receptor. The invention provides for a process for determining whether a chemical compound specifically binds to and activates a rat or human 5-HT,receptor. The invention additionally provides for a process for determining whether a chemical compound specifically binds to and inhibits activation of a rat or human 5-HT,receptor.

Uses of the 5-HT4 receptor

This invention provides isolated nucleic acid molecules encoding two mammalian GABA transporters, a mammalian taurine transporter and two human GABA transporters; methods of isolating these nucleic acid molecules and vectors comprising such nucleic acid molecules as well as mammalian cells comprising such vectors. Nucleic acid probes for detecting nucleic acid molecules encoding mammalian or human GABA transporters, or mammalian or human taurine transporters; antisense oligonucleotides complementary to any sequences of a nucleic acid molecule which encodes a mammalian GABA or taurine transporter or human GABA or taurine transporter; and antibodies to the mammalian GABA or taurine transporters, or human GABA or taurine transporters are provided. Pharmaceutical compounds related to mammalian GABA or taurine transporters and to human GABA or taurine transporters are provided. Nonhuman transgenic animals which express DNA encoding normal or mutant mammalian GABA or taurine transporters, or normal or mutant human GABA or taurine transporters are provided. Further provided are methods for determining substrate binding, detecting expression, drug screening, and treatments for alleviating abnormalities associated with mammalian GABA or taurine transporters, or human GABA or taurine transporters.

DNA encoding taurine and GABA transporters and uses thereof

This invention provides isolated nucleic acid molecules encoding a mammalian glycine transporter, isolated nucleic acid molecules encoding a human glycine transporter, isolated proteins which are mammalian glycine transporter proteins, isolated proteins which are human glycine transporter proteins, vectors comprising isolated nucleic acid molecules encoding a mammalian or a human glycine transporter, mammalian cells comprising such vectors, antibodies directed to a mammamlian glycine transporter, antibodies directed to a human glycine transporter, nucleic acid probes useful for detecting nucleic acid encoding mammalian glycine transporter, nucleic acid probes useful for detecting nucleic acid encoding human glycine transporter, antisense oligonucleotides complementary to any sequences of a nucleic acid molecule which encodes a mammalian glycine transporter, antisense oligonucleotides complementary to any sequences of a nucleic said molecule which encodes a human glycine transporter, pharmaceutical compounds related to mammalian glycine transporter and nonhuman transporter, pharmaceutical compounds related to human glycine transporter and nonhuman transgenic animals which express DNA encoding a normal or a mutant mammalian or human glycine transorter. This invention also provides methods for determining ligand binding, detecting expression, drug screening, and treatments for alleviating abnormalities associated with mammalian glycine transporter. This invention further provides methods for determining ligand binding, detecting expression, drug screening, and treatments for alleviating abnormalities associated with human glycine transporter.

DNA encoding a glycine transporter and uses thereof

This invention provides an isolated nucleic acid molecule encoding a human 5-HT.sub.1E receptor, an isolated protein which is a human 5-HT.sub.1E receptor, vectors comprising an isolated nucleic acid molecule encoding a human 5-HT.sub.1E receptors, mammalian cells comprising such vectors, antibodies directed to the human 5-HT.sub.1E receptor, nucleic acid probes useful for detecting nucleic acid encoding human 5-HT.sub.1E receptors, antisense oligonucleotides complementary to any sequences of a nucleic acid molecule which encodes a human 5-HT.sub.1E at receptor, pharmaceutical compounds related to human 5-HT.sub.1E receptors, and nonhuman transgenic animals which express DNA a normal or a mutant human 5-HT.sub.1E receptor. This invention further provides methods for determining ligand binding, detecting expression, drug screening, and treatment involving the human 5-HT.sub.1E receptor.

Methods for identifying a compound that binds to a human 5-HT.sub.1E

Use of alpha-1C specific compounds to treat benign prostatic hyperplasia

.alpha..sub.1C specific compounds to treat benign prostatic hyperplasia

This invention provides isolated nucleic acid molecules encoding human 5-HT.sub.1D receptors, isolated proteins which are human 5-HT.sub.1D receptors, vectors comprising isolated nucleic acid molecules encoding human 5-HT.sub.1D receptors, mammalian cells comprising such vectors, antibodies directed to human 5-HT.sub.1D receptors, nucleic acid probes useful for detecting nucleic acid encoding human 5-HT.sub.1D receptors, antisense oligonucleotides complementary to any sequences of a nucleic acid molecule which encodes a human 5-HT.sub.1D receptor, pharmaceutical compounds related to human 5-HT.sub.1D receptors, and nonhuman transgenic animals which express DNA which encodes a normal or a mutant human 5-HT.sub.1D receptor. This invention further provides methods for determining ligand binding, detecting expression, drug screening, and treatment involving the human 5-HT.sub.1D receptor.

Methods of treating migraine and compounds useful for such methods

The present invention provides an isolated nucleic acid molecule encoding a 5-HT.sub.2 receptor, and an isolated protein which is a human 5-HT.sub.2 receptor. The invention also provides vectors comprising DNA molecules encoding a human 5-HT.sub.2 receptor, and vectors adapted for expression of the 5-HT.sub.2 receptor in bacterial, yeast, or mammalian cells. In addition, the invention provides a DNA probe useful for detecting nucleic acid encoding the 5-HT.sub.2 receptor, a method for determining whether a ligand which is not known to be capable of binding to the 5-HT.sub.2 receptor can bind to the 5-HT.sub.2 receptor, a method for detecting the presence of 5-HT.sub.2 receptor on the surface of a cell, and a method of screening drugs to identify drugs which specifically interact with, and bind to, the 5-HT.sub.2 receptor. The invention herein also concerns an antibody directed to the human 5-HT.sub.2 receptor, such as a monoclonal antibody directed to an epitope of the 5-HT.sub.2 receptor present on the surface of a cell and having an amino acid sequence included within the amino acid sequence shown in FIGS. 2A-2G.

Growing community of inventors

Mahwah, NJ, United States of America

Paul R Hartig